Civic IQ
PROFESSIONAL_SERVICESONGOING

Acentra Health SUPPORT Act Criteria Report 2026

Acentra Health prepares 2026 SUPPORT Act DUR report

Texas Health and Human ServicesACENTRA HEALTHApril 19, 2026

Trusted by teams at

Motive logo
Veritone logo
TerraCycle logo
Cyvl logo
WithersRavenel logo
Derivita logo
Comcate logo
SafeTouch logo
IANS Research logo
Motive logo
Veritone logo
TerraCycle logo
Cyvl logo
WithersRavenel logo
Derivita logo
Comcate logo
SafeTouch logo
IANS Research logo
Motive logo
Veritone logo
TerraCycle logo
Cyvl logo
WithersRavenel logo
Derivita logo
Comcate logo
SafeTouch logo
IANS Research logo
Motive logo
Veritone logo
TerraCycle logo
Cyvl logo
WithersRavenel logo
Derivita logo
Comcate logo
SafeTouch logo
IANS Research logo

Description

Texas Medicaid’s drug utilization review program is supported by Acentra Health, which prepared the 2026 SUPPORT Act criteria report outlining opioid safety, pediatric antipsychotic monitoring, and fraud and abuse interventions. The biannual report provides detailed intervention criteria and population targets to demonstrate compliance with federal Medicaid pharmacy requirements under the SUPPORT Act.

Contract Details

Vendor

ACENTRA HEALTH

Agency

Texas Health and Human Services, TX

Contract Type

PROFESSIONAL_SERVICES

Document Date

April 19, 2026

Contract Term

Biannual SUPPORT Act DUR criteria review and reporting for 2026

Renewal Info

The report notes Texas must demonstrate compliance with federal Medicaid pharmacy requirements on a biannual basis, implying a recurring engagement for SUPPORT Act criteria review and reporting that may renew every two years.

More from ACENTRA HEALTH

Related Contracts

Bring us your territory.
We'll show you what is forming.

See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.

Try Civic IQ for free